文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

HIV感染者接种23价肺炎球菌荚膜多糖疫苗的有效性、安全性与成本效益评价

Evaluation of effectiveness, safety and cost-benefit of the 23- valent pneumococcal capsular polysaccharide vaccine for HIV-Infected patients.
PubMed 文献 · Vaccine · 2021-11-29

本研究纳入60名从未接种过任何肺炎球菌疫苗的HIV感染成人,自愿接种PPV23并随访一年。接种12个月时76.67%(46/60)患者出现血清学应答;接种组肺炎球菌性肺炎1例(1.67%,1/60),未接种组11例(9.17%,11/120),Fisher精确概率P=0.225,疫苗有效性81.79%,人均效益39.32美元,效益成本比1.19;PPV23耐受良好,未报告不良反应。

要点

  • 接种12个月时76.67%(46/60)HIV感染者出现血清学应答。
  • 接种组肺炎球菌性肺炎1例(1.67%,1/60),未接种组11例(9.17%,11/120),P=0.225。
  • 疫苗有效性81.79%,人均效益39.32美元,效益成本比1.19。

核心结论

  • PPV23可安全有效地用于HIV-1感染者,并能有效预防链球菌性肺炎。
  • 考虑到HIV感染者接种的成本效益,作者认为未来有必要在HIV感染者中推广该疫苗的广泛使用。

研究设计与样本

  • 研究纳入蓝山县60名从未接种过任何肺炎球菌疫苗的HIV感染成人,自愿接种PPV23并完成接种后一年随访。

主要发现

  • 接种12个月时76.67%(46/60)患者出现血清学应答,CD4计数(≤500 cells/ul或>500 cells/ul)及诊断至首次抗病毒治疗时间(≤1个月或>1个月)与抗体应答相关(p<0.05)。
  • 接种后一年内接种组肺炎球菌性肺炎1例(1.67%,1/60),未接种组11例(9.17%,11/120),Fisher精确概率P=0.225;疫苗有效性81.79%。
  • 人均效益39.32美元,效益成本比1.19。
  • 接种组与未接种组在接种后一年内门诊费用(p<0.05,95%CI:9.29-32.11)、药品费用(p=0.017,95%CI:2.47-24.44)及疾病相关间接费用(p=0.038,95%CI:0.93-33.63)方面差异有统计学意义。
  • PPV23耐受良好,未报告不良反应。

临床怎么用

  • 作者认为,基于本研究的成本效益结果,未来有必要在HIV感染者中推广PPV23的广泛使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Due to the lack of understanding of the protective effects and safety of 23-valent pneumococcal polysaccharide vaccine (PPV23) in immune-deficient populations, the vaccination rate of PPV23 among HIV-infected patients is still very low in China. The main objectives of this study were to determine whether the efforts to assess measures for the prevention of pneumococcal pneumonia are still worthwhile, and provide designated vaccination program of HIV-infected persons for government policy based on. METHODS: 60 HIV-infected adults in Lanshan county who had never been vaccinated with any pneumococcal vaccine were enrolled in this study, voluntary vaccination of PPV23 and One-year follow-up after vaccination can be completed. RESULT: 76.67% patients (46/60) had serologic response at 12 months after vaccine, CD4 count(≤500 cells/ul or > 500 cells/ul) and Month from diagnosis to first antiviral therapy (≤1 month or > 1 month) were related to antibody responses (p < 0.05).In this study, PPV23 was well tolerated, no adversereaction was reported.11 Streptococcus pneumoniae pneumonia (9.17%,11/120) occurred in the Unvaccinated group and 1 case(1.67%,1/60)in the vaccination group within one year after vaccination(Fisher's exact probability, P = 0.225). The VE was 81.79%. The per capita benefit was 39.32 dollars, thebenefit-costratio = 1.19. There are significant statistical differences between the vaccinated group and the non-vaccinated group in outpatient costs (p < 0.05, 95 %CI: 9.29-32.11), Medicine costs (p = 0.017, 95 %CI: 2.47-24.44), and disease related indirect costs (p = 0.038, 95 %CI: 0.93-33.63) within one year of vaccination. CONCLUSION: Our study results showed that PPV23 can be safely and effectively administered to HIV-1 infected individuals and effectively preventing Streptococcal pneumonia. Considering the cost-benefit of vaccination among HIV-infected persons, as it has been reported in our study, it is necessary to promote the widespread use of the vaccine among HIV-infected persons in the future.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Zou X, He J, Zheng J, et al. Evaluation of effectiveness, safety and cost-benefit of the 23- valent pneumococcal capsular polysaccharide vaccine for HIV-Infected patients. Vaccine. 2021. PMID: 34857419. doi:10.1016/j.vaccine.2021.11.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。